Patients with cancer are more vulnerable to severe COVID-19. As a result, routine SARS-CoV-2 testing of asymptomatic patients with cancer is recommended prior to treatment. However, there is limited evidence of its clinical usefulness. The objective of this study is to evaluate the value of routine testing of asymptomatic patients with cancer. Asymptomatic patients with cancer attending Odette Cancer Centre (Toronto, ON, Canada) were tested for SARS-CoV-2 prior to and during treatment cycles. Results were compared to positivity rates of SARS-CoV-2 locally and provincially. All 890 asymptomatic patients tested negative. Positivity rates in the province were 1.5%, in hospital were 1.0%, and among OCC's symptomatic cancer patients were 0% over the study period. Given our findings and the low SARS-CoV-2 community positivity rates, we recommend a dynamic testing model of asymptomatic patients that triggers testing during increasing community positivity rates of SARS-CoV-2.

中文翻译：

---

在治疗前和治疗期间对无症状癌症患者进行 SARS-CoV-2 检测：单一中心经验

癌症患者更容易感染严重的 COVID-19。因此，建议在治疗前对无症状的癌症患者进行常规 SARS-CoV-2 检测。然而，关于其临床有用性的证据有限。本研究的目的是评估无症状癌症患者常规检测的价值。Odette 癌症中心（加拿大安大略省多伦多）的无症状癌症患者在治疗周期之前和期间接受了 SARS-CoV-2 检测。结果与当地和省级的 SARS-CoV-2 阳性率进行了比较。所有 890 名无症状患者的检测结果均为阴性。研究期间，全省阳性率为 1.5%，住院率为 1.0%，OCC 有症状的癌症患者中阳性率为 0%。鉴于我们的发现和 SARS-CoV-2 社区的低阳性率，